Repare Therapeutics Inc. (NASDAQ:RPTX) Stock Holdings Lessened by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC lessened its stake in Repare Therapeutics Inc. (NASDAQ:RPTX) by 42.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 100,000 shares of the company’s stock after selling 73,351 shares during the quarter. Affinity Asset Advisors LLC owned 0.24% of Repare Therapeutics worth $131,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RPTX. Barclays PLC raised its holdings in shares of Repare Therapeutics by 1,471.7% during the third quarter. Barclays PLC now owns 8,330 shares of the company’s stock worth $29,000 after acquiring an additional 7,800 shares in the last quarter. Vontobel Holding Ltd. grew its stake in shares of Repare Therapeutics by 45.8% in the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company’s stock valued at $46,000 after buying an additional 11,000 shares in the last quarter. Stifel Financial Corp grew its stake in shares of Repare Therapeutics by 36.4% in the 3rd quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock valued at $178,000 after buying an additional 13,800 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Repare Therapeutics by 2,144,950.0% in the fourth quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company’s stock worth $112,000 after buying an additional 85,798 shares during the last quarter. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Stock Performance

Shares of NASDAQ:RPTX opened at $0.93 on Tuesday. The stock’s 50-day moving average is $1.12 and its 200-day moving average is $2.01. Repare Therapeutics Inc. has a 52-week low of $0.89 and a 52-week high of $4.29. The company has a market cap of $39.46 million, a P/E ratio of -0.46 and a beta of 0.91.

Repare Therapeutics (NASDAQ:RPTX) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.10. Repare Therapeutics had a negative return on equity of 40.87% and a negative net margin of 99.76%. As a group, equities analysts predict that Repare Therapeutics Inc. will post -2.04 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on RPTX shares. HC Wainwright dropped their price target on shares of Repare Therapeutics from $10.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Bloom Burton lowered Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 10th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.